²é¿´: 559  |  »Ø¸´: 2
±¾Ìû²úÉú 1 ¸ö ·­ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴
µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû

ygy19901025

ľ³æ (ÖøÃûдÊÖ)

[ÇóÖú] ÉúÎïÀàÕªÒª£¬Çó·­ÒëÓ¢Ò뺺£¬½ð±Ò·îÉÏ

Abstract
Glycogen synthase kinase-3¦Â (GSK-3¦Â), a key regulator of neuronal apoptosis, is inhibited by the phosphorylation of Ser-9/Ser-389 and was recently shown to be cleaved by calpain at the N terminus, leading to its subsequent activation. In this study calpain was found to cleave GSK-3¦Â not only at the N terminus but also at the C terminus, and cleavage sites were identified at residues Thr-38¨CThr-39 and Ile-384¨CGln-385. Furthermore, the cleavage of GSK-3¦Â occurred in tandem with Ser-9 dephosphorylation during cerebellar granule neuron apoptosis. Increasing Ser-9 phosphorylation of GSK-3¦Â by inhibiting phosphatase 1/2A or pretreating with purified active Akt inhibited calpain-mediated cleavage of GSK-3¦Â at both N and C termini, whereas non-phosphorylatable mutant GSK-3¦Â S9A facilitated its cleavage. In contrast, Ser-389 phosphorylation selectively inhibited the cleavage of GSK-3¦Â at the C terminus but not the N terminus. Calpain-mediated cleavage resulted in three truncated products, all of which contained an intact kinase domain: ¦¤N-GSK-3¦Â (amino acids 39¨C420), ¦¤C-GSK-3¦Â (amino acids 1¨C384), and ¦¤N/¦¤C-GSK-3¦Â (amino acids 39¨C384). All three truncated products showed increased kinase and pro-apoptotic activity, with ¦¤N/¦¤C-GSK-3¦Â being the most active form. This observation suggests that the GSK-3¦Â C terminus acts as an autoinhibitory domain similar to the N terminus. Taken together, these findings demonstrate that calpain-mediated cleavage activates GSK-3¦Â by removing its N- and C-terminal autoinhibitory domains and that Ser-9 phosphorylation inhibits the cleavage of GSK-3¦Â at both termini. In contrast, Ser-389 phosphorylation inhibits only C-terminal cleavage but not N-terminal cleavage. These findings also identify a mechanism by which site-specific phosphorylation and calpain-mediated cleavage operate in concert to regulate GSK-3¦Â activity.

» ²ÂÄãϲ»¶

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

wangyuan0929

½ð³æ (СÓÐÃûÆø)

¡¾´ð°¸¡¿Ó¦Öú»ØÌû

¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ...
ygy19901025: ½ð±Ò+100, ·­ÒëEPI+1, ¡ï¡ï¡ï¡ï¡ï×î¼Ñ´ð°¸ 2014-03-13 22:11:24
Abstract
ÕªÒª
Glycogen synthase kinase-3¦Â (GSK-3¦Â), a key regulator of neuronal apoptosis, is inhibited by the phosphorylation of Ser-9/Ser-389 and was recently shown to be cleaved by calpain at the N terminus, leading to its subsequent activation.
ÌÇÔ­ºÏ³Éø¼¤Ã¸-3¦Â£¨GSK-3¦Â£©£¬ÊÇÉñ¾­ÔªµòÍöµÄ¹Ø¼üµ÷¿ØÎïÖÊ£¬»áÊܵ½Ser-9/Ser-389λµãÁ×ËữµÄÒÖÖÆ£¬×î½ü·¢ÏÖËü¿ÉÒÔ±»¸Æµ°°×øÔÚN¶ËÇжϣ¬ÕâÒ»·´Ó¦Ëæºó½«Æä»î»¯¡£
In this study calpain was found to cleave GSK-3¦Â not only at the N terminus but also at the C terminus, and cleavage sites were identified at residues Thr-38¨CThr-39 and Ile-384¨CGln-385.
±¾Ñо¿Öз¢ÏָƵ°°×ø²»½öÄÜÇжÏGSK-3¦ÂµÄN¶Ë£¬»¹¿ÉÒÔÇпªÆäCÄ©¶Ë£¬²¢È·¶¨ÁËÆäøÇÐλµãΪThr-38/Thr-39ºÍIle-384/Gln-385ÕâÁ½¶Ô°±»ùËá²Ð»ùÖ®¼ä¡£
Furthermore, the cleavage of GSK-3¦Â occurred in tandem with Ser-9 dephosphorylation during cerebellar granule neuron apoptosis.
ÁíÍ⣬GSK-3¦ÂµÄÇжÏÊÇÓëSer-9µÄÈ¥Á×Ëữ¹ý³ÌÒ»Æð£¬ÔÚСÄÔ¿ÅÁ£Éñ¾­ÔªµòÍö¹ý³ÌÖз¢ÉúµÄ¡£
Increasing Ser-9 phosphorylation of GSK-3¦Â by inhibiting phosphatase 1/2A or pretreating with purified active Akt inhibited calpain-mediated cleavage of GSK-3¦Â at both N and C termini, whereas non-phosphorylatable mutant GSK-3¦Â S9A facilitated its cleavage.
ͨ¹ýÒÖÖÆÁ×Ëáø1/2A»òÓô¿»¯¹ýµÄ»î»¯Ì¬µÄAkt½øÐÐÔ¤´¦Àí£¬À´Ìá¸ßSer-9µÄÁ×Ëữ³Ì¶È£¬¿ÉÒÔÒÖÖÆ¸Æµ°°×ø½éµ¼µÄGSK-3¦ÂÔÚNÄ©¶ËºÍCÄ©¶Ë·¢ÉúµÄ¶ÏÁÑ£¬È»¶ø²»¿ÉÁ×ËữµÄGSK-3¦ÂÍ»±äÌåS9AÔòÄܹ»´Ù½øÆä¶ÏÁÑ¡£
In contrast, Ser-389 phosphorylation selectively inhibited the cleavage of GSK-3¦Â at the C terminus but not the N terminus.
Ïà±È֮ϣ¬Ser-389µÄÁ×ËữѡÔñÐÔµÄÒÖÖÆÁËGSK-3¦ÂÔÚCÄ©¶ËµÄ¶ÏÁÑ£¬¶ø¶ÔNÄ©¶ËûÓÐÓ°Ïì¡£
Calpain-mediated cleavage resulted in three truncated products, all of which contained an intact kinase domain: ¦¤N-GSK-3¦Â (amino acids 39¨C420), ¦¤C-GSK-3¦Â (amino acids 1¨C384), and ¦¤N/¦¤C-GSK-3¦Â (amino acids 39¨C384).
¸Æµ°°×ø½éµ¼µÄ¶ÏÁѲúÉúÁËÈýÖÖøÇвúÎËüÃǶ¼°üº¬ÁËÍêÕûµÄ¼¤Ã¸½á¹¹Óò£º¦¤N-GSK-3¦Â (°±»ùËá²Ð»ù39¨C420), ¦¤C-GSK-3¦Â (°±»ùËá²Ð»ù1¨C384), ÒÔ¼°¦¤N/¦¤C-GSK-3¦Â (°±»ùËá²Ð»ù39¨C384).
All three truncated products showed increased kinase and pro-apoptotic activity, with ¦¤N/¦¤C-GSK-3¦Â being the most active form.
ËùÓÐÕâÈýÖÖøÇвúÎïÏÔʾ³öÁ˸ü¸ßµÄ¼¤Ã¸»îÐÔÒÔ¼°´ÙµòÍö»îÐÔ£¬ÆäÖÐ ¦¤N/¦¤C-GSK-3¦Â »îÐÔ×î¸ß¡£
This observation suggests that the GSK-3¦Â C terminus acts as an autoinhibitory domain similar to the N terminus.
ÕâÒ»ÏÖÏóÏÔʾ³öGSK-3¦ÂµÄCÄ©¶ËÓëNÄ©¶ËÀàËÆ£¬¶¼ÊÇÒ»ÖÖÆð×ÔÎÒÒÖÖÆ×÷ÓõĽṹÓò¡£
Taken together, these findings demonstrate that calpain-mediated cleavage activates GSK-3¦Â by removing its N- and C-terminal autoinhibitory domains and that Ser-9 phosphorylation inhibits the cleavage of GSK-3¦Â at both termini.
×ÛÉÏËùÊö£¬ÕâЩ·¢ÏÖÏÔʾ³ö£º¸Æµ°°×ø½éµ¼µÄ¶ÏÁÑÒÆ³ýÁËNÄ©¶ËºÍCÄ©¶ËµÄ×ÔÎÒÒÖÖÆ½á¹¹Óò£¬´Ó¶ø»î»¯ÁËGSK-3¦Â£¬Ser-9µÄÁ×Ëữ×÷ÓÃÒÖÖÆÁËGSK-3¦ÂµÄÁ½¸öÄ©¶Ë·¢ÉúµÄ¶ÏÁÑ·´Ó¦¡£
In contrast, Ser-389 phosphorylation inhibits only C-terminal cleavage but not N-terminal cleavage.
Ïà±È֮ϣ¬Ser-389µÄÁ×ËữֻÄÜÒ»Ö±CÄ©¶ËµÄ¶ÏÁÑ£¬¶ø²»ÒÖÖÆNÄ©¶Ë¶ÏÁÑ¡£
These findings also identify a mechanism by which site-specific phosphorylation and calpain-mediated cleavage operate in concert to regulate GSK-3¦Â activity.
ÕâЩ·¢ÏÖ»¹È·¶¨ÁËÒ»¸öλµãÌØÒìÐÔÁ×Ëữ×÷Óú͸Ƶ°°×ø½éµ¼µÄ¶ÏÁÑ×÷ÓÃÒ»Æëµ÷½ÚGSK-3¦ÂµÄ»îÐÔµÄ×÷ÓûúÖÆ¡£
3Â¥2014-03-13 14:48:38
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
²é¿´È«²¿ 3 ¸ö»Ø´ð

ygy19901025

ľ³æ (ÖøÃûдÊÖ)

ÔõôûÈ˻ظ´ÄØ
2Â¥2014-03-13 12:40:31
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] 330Çóµ÷¼Á +3 С²Ä»¯±¾¿Æ 2026-03-18 3/150 2026-03-18 21:55 by ÎÞи¿É»÷111
[¿¼ÑÐ] 281Çóµ÷¼Á£¨0805£© +6 ÑÌÏ«Ò亣 2026-03-16 15/750 2026-03-18 21:12 by Gaodh_82
[¿¼ÑÐ] 085600²ÄÁÏÓ뻯¹¤ +5 °²È«Éϰ¶£¡ 2026-03-16 5/250 2026-03-18 15:33 by cmz0325
[¿¼ÑÐ] ²ÄÁÏר˶306Ó¢Ò»Êý¶þ +10 z1z2z3879 2026-03-16 13/650 2026-03-18 14:20 by 007_lilei
[¿¼ÑÐ] 280Çóµ÷¼Á +6 ¹¾ààÏþÏþ 2026-03-18 7/350 2026-03-18 11:25 by Î޼ʵIJÝÔ­
[¿¼ÑÐ] 303Çóµ÷¼Á +4 î£08 2026-03-17 6/300 2026-03-18 11:01 by Iveryant
[¿¼ÑÐ] 296Çóµ÷¼Á +5 ´ó¿Ú³Ô·¹ ÉíÌ彡 2026-03-13 5/250 2026-03-17 21:05 by ²»»ó¿ÉÀÖ
[¿¼ÑÐ] ²ÄÁϹ¤³Ìר˶274Ò»Ö¾Ô¸211Çóµ÷¼Á +6 Ñ¦ÔÆÅô 2026-03-15 6/300 2026-03-17 11:05 by ѧԱh26Tkc
[¿¼ÑÐ] Ò»Ö¾Ô¸ÄϾ©´óѧ£¬080500²ÄÁÏ¿ÆÑ§Ó빤³Ì£¬µ÷¼Á +4 Jy? 2026-03-16 4/200 2026-03-17 11:02 by gaoqiong
[¿¼ÑÐ] 0703 ÎïÀí»¯Ñ§µ÷¼Á +3 ÎÒ¿ÉÒÔÉϰ¶µÄ¶Ô 2026-03-13 5/250 2026-03-16 10:50 by ÎÒ¿ÉÒÔÉϰ¶µÄ¶ÔÂ
[¿¼ÑÐ] 080500£¬²ÄÁÏѧ˶302·ÖÇóµ÷¼ÁѧУ +4 ³õʶ¿ÉÀÖ 2026-03-14 5/250 2026-03-14 21:08 by peike
[¿¼ÑÐ] 0856²ÄÁÏÓ뻯¹¤301Çóµ÷¼Á +5 ÞÈÊø¹â 2026-03-13 5/250 2026-03-13 22:00 by ÐÇ¿ÕÐÇÔÂ
[¿¼ÑÐ] 311Çóµ÷¼Á +3 ¶¬Ê®Èý 2026-03-13 3/150 2026-03-13 20:41 by JourneyLucky
[˶²©¼ÒÔ°] 085600 260·ÖÇóµ÷¼Á +3 Ìì¿Õ»¹ÏÂÓêô 2026-03-13 5/250 2026-03-13 18:46 by Ìì¿Õ»¹ÏÂÓêô
[¿¼ÑÐ] Çóµ÷¼Á +5 Ò»¶¨ÓÐѧÉÏ- 2026-03-12 5/250 2026-03-13 18:31 by ms629
[¿¼ÑÐ] ¿¼Ñе÷¼Á +4 ·Ò´ï46 2026-03-12 4/200 2026-03-13 16:04 by ruiyingmiao
[¿¼ÑÐ] Çóµ÷¼Á +3 ³ÌÓ꺼 2026-03-12 3/150 2026-03-13 15:06 by JourneyLucky
[¿¼ÑÐ] ²ÄÁÏ301·ÖÇóµ÷¼Á +5 Liyouyumairs 2026-03-12 5/250 2026-03-13 14:42 by JourneyLucky
[¿¼ÑÐ] 289Çóµ÷¼Á +3 ÀîÕþÓ¨ 2026-03-12 3/150 2026-03-13 11:02 by Çóµ÷¼Ázz
[¿¼ÑÐ] 290Çóµ÷¼Á +3 ADT 2026-03-13 3/150 2026-03-13 10:19 by peike
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û